Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 85

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 85
---
-down conditions related to the accuracy of the parties’ respective representations, 
 warranties and pre-Closing covenants in the Merger Agreement;                             |

| ● | FutureTech’s                                                                                 
 registration statement to be filed with the United States Securities and Exchange Commission 
 shall have become effective; and                                                             |

| 29 |

| ● | FutureTech’s          
 stockholder approval. |

In addition, the obligation of FutureTech to consummate the Transactions is also conditioned upon, among other items, the closing of the Target Acquisitions, which such condition may be waived by FutureTech, subject to compliance with applicable law. To the extent that the FutureTech Board determines that any modifications by the parties, including any waivers of any conditions to the Closing, materially change the terms of the Business Combination, FutureTech will notify its stockholders in a manner reasonably calculated to inform them about the modifications as may be required by law, by publishing a press release, filing a Current Report on Form 8-K and/or circulating a supplement to this proxy statement/prospectus.

See the section entitled “ Proposal No. 1 — The Business Combination Proposal — Summary of the Merger Agreement — Conditions to Closing” for additional information.

Following the consummation of the Business Combination, our only significant asset will be our ownership interest in Longevity, and such ownership may not be sufficient to pay dividends or make distributions or

loans to enable us to pay any dividends on FutureTech Common Stock or satisfy our other financial obligations.

Following the consummation of the Business Combination, we will have no direct operations and no significant assets other than its ownership of Longevity. Longevity’s stockholders immediately prior to the Business Combination will become stockholders of FutureTech. We will depend on Longevity for distributions, loans and other payments to generate the funds necessary to meet our financial obligations, including our expenses as a publicly traded company and to pay any dividends with respect to FutureTech Common Stock. The financial condition and operating requirements of Longevity may limit our ability to obtain cash from Longevity. The earnings from, or other available assets of, Longevity may not be sufficient to pay dividends or make distributions or loans to enable us to pay any dividends on FutureTech Common Stock or satisfy our other financial obligations.

This lack of diversification may subject us to numerous economic, competitive and regulatory risks, any or all of which may have a substantial adverse impact upon our financial condition and results of operations.

FutureTech has no specified maximum redemption threshold. The absence of such a redemption threshold may make it